These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 38009200)
1. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200 [No Abstract] [Full Text] [Related]
2. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients. Zheng X; Fang M; Fan Y; Sun Y; Sun M; Yang A; Zhang B; Liu Q; Liu H; Zhou X; Huang T; Qin J; Wang Z; Qin M; Shen Z; Yao S; Yang J; Wang Y; Gao M Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38261313 [TBL] [Abstract][Full Text] [Related]
4. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032 [TBL] [Abstract][Full Text] [Related]
5. Durability of Response With Selpercatinib in Patients With Wirth LJ; Brose MS; Subbiah V; Worden F; Solomon B; Robinson B; Hadoux J; Tomasini P; Weiler D; Deschler-Baier B; Tan DSW; Maeda P; Lin Y; Singh R; Bayt T; Drilon A; Cassier PA J Clin Oncol; 2024 Sep; 42(27):3187-3195. PubMed ID: 39094065 [No Abstract] [Full Text] [Related]
6. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500 [No Abstract] [Full Text] [Related]
7. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Griesinger F; Curigliano G; Thomas M; Subbiah V; Baik CS; Tan DSW; Lee DH; Misch D; Garralda E; Kim DW; van der Wekken AJ; Gainor JF; Paz-Ares L; Liu SV; Kalemkerian GP; Houvras Y; Bowles DW; Mansfield AS; Lin JJ; Smoljanovic V; Rahman A; Kong S; Zalutskaya A; Louie-Gao M; Boral AL; Mazières J Ann Oncol; 2022 Nov; 33(11):1168-1178. PubMed ID: 35973665 [TBL] [Abstract][Full Text] [Related]
8. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Gainor JF; Curigliano G; Kim DW; Lee DH; Besse B; Baik CS; Doebele RC; Cassier PA; Lopes G; Tan DSW; Garralda E; Paz-Ares LG; Cho BC; Gadgeel SM; Thomas M; Liu SV; Taylor MH; Mansfield AS; Zhu VW; Clifford C; Zhang H; Palmer M; Green J; Turner CD; Subbiah V Lancet Oncol; 2021 Jul; 22(7):959-969. PubMed ID: 34118197 [TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With Kim J; Bradford D; Larkins E; Pai-Scherf LH; Chatterjee S; Mishra-Kalyani PS; Wearne E; Helms WS; Ayyoub A; Bi Y; Sun J; Charlab R; Liu J; Zhao H; Liang D; Ghosh S; Philip R; Pazdur R; Theoret MR; Beaver JA; Singh H Clin Cancer Res; 2021 Oct; 27(20):5452-5456. PubMed ID: 34045295 [TBL] [Abstract][Full Text] [Related]
10. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231 [TBL] [Abstract][Full Text] [Related]
11. Exposure-Response Relationships for Pralsetinib in Patients with RET-Altered Thyroid Cancer or RET Fusion-Positive Nonsmall Cell Lung Cancer. Kassir N; McDougall D; Kuruvilla D; Kim S; Kumar S; Rahman A; Ruf T; Cheeti S; Ankrom W J Clin Pharmacol; 2024 Jun; 64(6):685-696. PubMed ID: 38337106 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer. Zhou Q; Zhao J; Chang J; Wang H; Fan Y; Wang K; Wu G; Nian W; Sun Y; Sun M; Wang X; Shi H; Zheng X; Yao S; Qin M; Shen Z; Yang J; Wu YL Cancer; 2023 Oct; 129(20):3239-3251. PubMed ID: 37282666 [TBL] [Abstract][Full Text] [Related]
13. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914 [No Abstract] [Full Text] [Related]
14. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Sherman SI; Clary DO; Elisei R; Schlumberger MJ; Cohen EE; Schöffski P; Wirth LJ; Mangeshkar M; Aftab DT; Brose MS Cancer; 2016 Dec; 122(24):3856-3864. PubMed ID: 27525386 [TBL] [Abstract][Full Text] [Related]
15. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment. Dabelić N; Jukić T; Fröbe A Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884 [TBL] [Abstract][Full Text] [Related]
16. SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY. Uchino K; Komoda M; Tomomatsu J; Okamoto T; Horiuchi K; Tsuji A; Ito Y; Todo T; Rito K; Takahashi S Endocr Pract; 2017 Feb; 23(2):149-156. PubMed ID: 27819766 [TBL] [Abstract][Full Text] [Related]
17. Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers. Ali F; Neha K; Chauhan G Arch Pharm Res; 2022 May; 45(5):309-327. PubMed ID: 35598228 [TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial. Wirth LJ; Robinson B; Boni V; Tan DSW; McCoach C; Massarelli E; Hess LM; Jen MH; Kherani J; Olek E; Subbiah V Oncologist; 2022 Feb; 27(1):13-21. PubMed ID: 34516023 [TBL] [Abstract][Full Text] [Related]
19. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Subbiah V; Cassier PA; Siena S; Garralda E; Paz-Ares L; Garrido P; Nadal E; Vuky J; Lopes G; Kalemkerian GP; Bowles DW; Seetharam M; Chang J; Zhang H; Green J; Zalutskaya A; Schuler M; Fan Y; Curigliano G Nat Med; 2022 Aug; 28(8):1640-1645. PubMed ID: 35962206 [TBL] [Abstract][Full Text] [Related]